BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-244@pharmaconomics
DTSTAMP:20260707T034515Z
DTSTART;VALUE=DATE:20260309
DTEND;VALUE=DATE:20260310
SUMMARY:MLYS Phase 2 — lorundrostat
DESCRIPTION:Phase 2 trial results for lorundrostat in hypertension are due Mar 9\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm\n\nTrack it: https://www.pharmaconomics.com/e/244
URL:https://www.pharmaconomics.com/e/244
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MLYS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR